Insulin Therapy

Insulin therapy is the absolute cornerstone of treatment for type 1 diabetes mellitus and is also a fundamental therapeutic resource in type 2 diabetes mellitus, gestational diabetes and numerous specific forms of diabetes. Its clinical importance derives from the fact that insulin is not merely a glucose-lowering medication, but the principal hormone governing postprandial anabolic regulation, suppression of hepatic glucose production, inhibition of lipolysis and ketogenesis, facilitation of peripheral glucose utilization and maintenance of systemic energy homeostasis. When endogenous secretion becomes absent, severely reduced or inadequate relative to the degree of insulin resistance, insulin replacement does more than correct blood glucose: it interrupts a pathophysiological cascade that would otherwise lead to catabolism, ketosis, dehydration, loss of lean mass and progression of organ damage.

From a therapeutic perspective, however, insulin therapy is not simply the prescription of a molecule. It requires reasoned construction of the regimen, selection of the insulin type, definition of when to start, progressive titration, integration with blood glucose self-monitoring or sensors, knowledge of factors that alter absorption and requirements, prevention of dose errors and robust therapeutic education. Modern insulin therapy should therefore be understood as an integrated clinical system in which pharmacology, technology, nutrition, physical activity, adherence and safety all contribute to achieving metabolic control.

The rationale for insulin therapy varies partly according to the type of diabetes, but always rests on the same biological principle: restoring, as far as possible, insulin availability compatible with the body's metabolic demands. In type 1 diabetes mellitus, insulin is mandatory and lifesaving because autoimmune beta-cell destruction leads to an absolute or near-absolute deficiency of endogenous secretion. In this setting, the objective is not merely to reduce hyperglycemia, but to replace a lost endocrine function and prevent diabetic ketoacidosis. In type 2 diabetes mellitus, by contrast, insulin is used mainly when endogenous secretion can no longer compensate for insulin resistance, when hyperglycemia is marked from presentation, when signs of catabolism are present or when control remains inadequate despite well-managed noninsulin therapy.

The decision to start insulin in type 2 diabetes should not be interpreted as treatment “failure,” but as a pathophysiologically coherent transition in the natural history of the disease. Progressive loss of beta-cell function, combined with increased hepatic glucose production and reduced peripheral uptake, means that in many patients oral or injectable noninsulin therapy, although useful, is no longer sufficient. The most recent guidelines emphasize that insulin should be considered in the presence of severe hyperglycemia, osmotic and catabolic symptoms, unintentional weight loss, ketosis or suspected substantial insulin deficiency; in these conditions, delaying its use prolongs glucotoxicity and worsens residual beta-cell function.

There are also clinical settings in which insulin is preferable even without permanent loss of endogenous secretion. These include pregnancy, numerous hospital settings, the perioperative period, certain acute infections, phases of metabolic decompensation, glucocorticoid use, post-transplant diabetes during particular clinical phases and many secondary forms of diabetes in which the speed, flexibility and potency of insulin action offer a practical advantage over other pharmacological classes. Insulin may also be used temporarily to overcome periods of metabolic instability and then potentially reduced or restructured as the clinical context and requirements change.

The rationale for insulin is not exclusively glucocentric. Correcting insulin deficiency means reducing the flux of free fatty acids from adipose tissue to the liver, restraining hepatic gluconeogenesis, inhibiting ketone-body production, improving protein anabolism, limiting osmotic dehydration and reducing the proinflammatory environment associated with persistent hyperglycemia. This explains why a well-designed insulin regimen can produce clinical benefits beyond a simple reduction in glycated hemoglobin, especially in forms with substantial decompensation or severe insulin deficiency.

Clinical indications must therefore be individualized. In type 1 diabetes, intensive replacement is pursued from onset. In type 2 diabetes, clinicians assess the relative contributions of secretory deficiency, insulin resistance, clinical frailty, hypoglycemic risk, comorbidities, self-management capacity, technological resources and individualized glycemic goals. Modern insulin therapy is no longer a monolithic block, but a set of scalable strategies ranging from simple basal insulin initiation to automated infusion systems.

Available insulins differ in structure, absorption kinetics, onset of action, peak, duration and intraindividual variability. This pharmacological diversity forms the basis on which different treatment regimens are constructed. Prandial insulins include regular human insulin and rapid- or ultra-rapid-acting analogues developed to approximate the physiological postprandial insulin peak as closely as possible. Compared with regular human insulin, rapid-acting analogues generally have an earlier onset of action, require less advance administration before a meal and adapt better to real-world meals, while ultra-rapid formulations extend this approach further by reducing the delay between administration and absorption.

Basal insulins, by contrast, are intended to control hepatic glucose production between meals and overnight. Historically, neutral protamine Hagedorn insulin, known as NPH, was the classic model of basal coverage, but its pharmacokinetics are characterized by greater variability, a relatively pronounced peak and a duration often shorter than 24 hours. Long-acting basal analogues, such as glargine and detemir, and ultra-long-acting analogues, such as degludec or high-concentration glargine, were developed to provide flatter, more predictable and more prolonged coverage, reducing the risk of hypoglycemia, particularly nocturnal hypoglycemia, in many clinical settings.

A distinct category is represented by premixed insulins, which combine fixed proportions of a prandial component and an intermediate-acting or protaminated component. These formulations can simplify certain treatment regimens, particularly in type 2 diabetes, but provide less flexibility than basal-bolus regimens because the basal and prandial components cannot be adjusted independently. Their usefulness therefore depends on regular daily schedules, meal composition and the need for a simpler approach.

Another pharmacologically relevant aspect is concentration. In addition to standard U100 formulations, concentrated insulins such as U200, U300 and U500 are available and are used to improve injection comfort, reduce the injected volume or manage patients with very high requirements. Concentrated formulations are not intuitively interchangeable with standard formulations and require particular prescribing and educational attention, because differences in devices, volume and kinetics can promote administration errors unless explained precisely.

Insulin pharmacology depends not only on the molecule but also on the route and context of administration. Subcutaneous injection exposes absorption to local variables such as anatomical site, temperature, muscular activity, injection depth, presence of lipodystrophy and injected volume. Intravenous infusion, used in selected hospital settings and metabolic emergencies, eliminates much of this variability and permits very rapid control, but requires close monitoring. In clinical practice, understanding the actual pharmacokinetics of different insulins is essential for correctly interpreting apparently unexplained hypo- and hyperglycemia.

Initial setup should begin not with the molecule but with the patient's clinical profile. The type of diabetes, likely insulin reserve, severity of hyperglycemia, presence of symptoms, body weight, eating habits, kidney and liver function, hypoglycemic risk, level of health literacy, access to devices, biological age and the ability of the patient or caregiver to manage regimens of varying complexity must be clarified. In type 1 diabetes, the standard approach is intensive therapy with multiple daily injections or an insulin pump. In type 2 diabetes, treatment often begins with a single basal insulin that is titrated progressively, except in cases of marked decompensation requiring a more intensive strategy from the outset.

When basal insulin is initiated in type 2 diabetes, the rationale is first to correct fasting hyperglycemia and reduce overnight hepatic glucose production. The starting dose is generally established through a simplified empirical approach or according to body weight, but the decisive element is not so much the initial dose as the subsequent structured titration. The most common error is not starting too early, but starting and then failing to intensify. Basal insulin that is not titrated remains a theoretical treatment rather than a genuinely effective one.

In type 1 diabetes, the initial regimen should instead pursue reasonable physiological replacement from onset by distributing requirements between the basal component and mealtime boluses. This distribution requires subsequent adjustments based on glucose monitoring, meal carbohydrate content, insulin sensitivity at different times of day, physical activity and the clinical phase, including any initial partial remission. Intensive insulin therapy is not a fixed formula, but a continuous process of adjustment.

Main initial models of insulin therapy

• Basal insulin initiation with one basal insulin dose per day
• Basal-plus regimen with progressive addition of a bolus at the most critical meals
• Basal-bolus regimen with separate basal coverage and prandial boluses
• Premixed insulin regimens once or several times daily
• Continuous subcutaneous insulin infusion with an insulin pump

Selection among these models depends on the dominant problem. If fasting hyperglycemia predominates with relatively limited postprandial excursions, basal insulin may be sufficient. If marked postprandial hyperglycemia develops or control remains unsatisfactory despite improvement in fasting glucose, the prandial component must be addressed. In patients with regular routines who need simplification, premixed insulins may offer an intermediate option. In people with type 1 diabetes, high glycemic variability or strong motivation for self-management, insulin pumps and sensor-integrated systems may provide substantial advantages.

The initial plan should also include realistic goals, written instructions, hypoglycemia management, verification of injection technique, criteria for self-correction and a close follow-up plan from the outset. Insulin therapy without detailed initial education can rapidly become ineffective or dangerous even when the initial pharmacological prescription is theoretically correct.

Intensification of insulin therapy is the step through which the regimen is adapted to the patient's actual physiology and the evolution of the disease. In type 2 diabetes, this process often progresses from basal insulin alone to a basal-plus regimen and ultimately to a basal-bolus regimen, but this sequence is not mandatory. In some cases, the clinical problem is predominantly postprandial, and targeted addition of a bolus at the largest meal may be more rational than indefinitely increasing the basal dose. The phenomenon of overbasalization, meaning excessive escalation of basal insulin alone without adequate benefit on daytime excursions, increases the risk of hypoglycemia and weight gain without correcting the true defect in the glycemic profile.

In type 1 diabetes, personalization mainly concerns the relationship among basal dose, prandial boluses, sensitivity factor, insulin-to-carbohydrate ratio, glycemic targets and context-specific corrections. The aim is to approximate physiological secretion, which in reality varies from hour to hour. This variability depends on circadian rhythm, the dawn phenomenon, intercurrent illness, the menstrual cycle, exercise, sleep quality and meal content not only in carbohydrates but also in fats and proteins. A fixed regimen may therefore be sufficient during some phases, but rapidly becomes limiting in patients who require more nuanced management.

Personalization also concerns the device. Prefilled pens promote simplicity and precision in many settings. Insulin pumps make it possible to modulate basal delivery by time interval, suspend or reduce delivery in relation to hypoglycemic risk and use different bolus patterns for prolonged or mixed meals. Automated insulin delivery systems integrate a sensor and algorithm to modulate basal insulin and, in more advanced systems, also help manage boluses, increasing time in range and reducing the daily decision-making burden.

Personalization is also required in relation to therapeutic goals. A young person with type 1 diabetes, strong self-management skills and access to advanced technology may aim for tighter targets with little time in hypoglycemia. A frail older patient with cognitive decline or high fall risk instead requires simpler regimens and less aggressive goals. In both cases, treatment quality is measured not by the complexity of the regimen, but by its suitability for the actual clinical context.

Another crucial aspect of intensification is coordination with other therapies. In type 2 diabetes, combination with metformin, glucagon-like peptide 1 receptor agonists, that is GLP-1 (glucagon-like peptide 1), or other medications may permit lower insulin doses, better postprandial control, less weight gain and sometimes a lower hypoglycemic risk. Insulin should therefore not be regarded as an isolated therapy by definition, but as a component of an integrated metabolic strategy.

Insulin therapy is inseparable from glucose monitoring. Without reliable data, it is impossible to distinguish an insufficient dose from an excessive one or determine whether the dominant problem is fasting, postprandial, nocturnal or related to variability. Capillary blood glucose self-monitoring remains useful, particularly for titration, confirmation of symptomatic hypo- or hyperglycemia and certain immediate decisions. In patients treated with insulin, especially intensive regimens, however, glucose sensors have become central because they show the continuous trajectory rather than only an instantaneous glucose value.

Continuous glucose monitoring (CGM) and other forms of sensor-based monitoring make it possible to assess time in range, time in hypoglycemia, glycemic variability, overnight patterns, response to meals and the effect of exercise. This wealth of information has changed the very way insulin is titrated. The goal is no longer only to lower glycated hemoglobin, but to construct more stable and safer profiles. A patient with an acceptable glycated hemoglobin but wide fluctuations and numerous hypoglycemic episodes is not well controlled, and technology has made this much more visible.

Titration must be structured. The basal dose is adjusted in relation to fasting values and the overnight pattern, whereas boluses are modified according to postprandial response, carbohydrate quantity, residual active insulin and individual sensitivity. Good adjustment requires simple but consistent rules applied continuously. In clinical practice, titration often fails not because insulin is ineffective, but because of therapeutic inertia, vague instructions or excessive complexity of the directions.

Integrated sensor-pump systems have further changed monitoring because the data are used not only by the clinician and patient but also by the algorithm that modulates delivery. In hybrid closed-loop systems, the patient generally continues to announce meals, but the device automatically adapts part of insulin delivery in response to current values and their trend. The most recent guidelines recognize these systems as a preferred option for many people with type 1 diabetes and a growing proportion of people with type 2 diabetes treated with intensive regimens.

Monitoring should also include assessment of overall clinical outcomes: body weight, frequency of hypoglycemia, quality of life, treatment burden, need for caregiver assistance, financial sustainability and actual adherence. A regimen that achieves theoretical targets but is unmanageable in daily life does not represent good insulin therapy. Integration of glycemic data, clinical context and patient preferences is the core of modern follow-up.

Correct administration technique is an essential component of therapeutic efficacy. Insulin is absorbed from subcutaneous tissue at different rates depending on the site, injection depth, administered volume and tissue characteristics. In general, the abdomen provides faster and more predictable absorption for prandial insulins, whereas the thighs and buttocks may be used more frequently for basal insulins, although these are not absolute rules. Systematic site rotation is essential to prevent lipodystrophy and nodules caused by repeated injection at the same point, conditions that alter absorption substantially and unpredictably.

Needle characteristics, insertion angle, keeping the needle in place for several seconds after injection and avoiding excessive reuse of devices also affect administration quality. Apparently minor errors may explain wide glycemic fluctuations. In patients with unexplained poor control, direct inspection of injection sites and practical review of technique are often more useful than further pharmacological escalation.

Numerous systemic factors alter insulin requirements. Reduced kidney function tends to slow insulin clearance and may increase hypoglycemic risk. Liver disease, although its effects may be less linear, can alter both glucose metabolism and insulin availability. Infections, fever, pain, surgical stress and many acute illnesses increase counterregulatory hormonal activity and insulin requirements. Conversely, reduced food intake, vomiting, advanced kidney failure or sudden discontinuation of glucocorticoids may require prompt dose reduction.

Pharmacological interactions are clinically relevant. Glucocorticoids increase hepatic gluconeogenesis and insulin resistance, often producing postprandial and afternoon hyperglycemia that requires adaptation of insulin type and timing. Certain immunosuppressants, immune checkpoint inhibitors in selected cases, artificial nutrition, catecholamines, antipsychotics and other medications may alter the glycemic profile and insulin requirements. Alcohol, especially when consumed without adequate carbohydrate intake, may also increase the risk of delayed hypoglycemia by inhibiting hepatic gluconeogenesis.

Physical activity warrants separate consideration. Aerobic exercise often facilitates peripheral glucose uptake and increases the risk of hypoglycemia during or after activity, whereas anaerobic or high-intensity exercise may trigger counterregulatory responses with transient rises in blood glucose. The relationship between exercise and insulin doses is therefore not unidirectional. An individualized strategy is needed that considers timing, duration, intensity, active insulin at the time of activity and the risk of delayed nocturnal hypoglycemia.

In children and adolescents, insulin therapy must reconcile metabolic goals, growth, puberty, variable physical activity, changing insulin sensitivity and age-specific educational needs. Through increased counterregulatory hormones and physiological insulin resistance, puberty often makes higher doses necessary. Sensor-integrated systems and automated delivery have assumed an increasingly important role in this group because they help manage high variability, reduce family burden and improve time in range.

In older adults, safety is the dominant issue. Frailty, sarcopenia, visual impairment, cognitive decline, polypharmacy, kidney failure and fall risk profoundly alter the benefit-risk balance of insulin therapy. In these patients, simplifying regimens, favoring approaches with less exposure to hypoglycemia and individualizing targets are often more important than achieving particularly stringent values. Recent guidelines also emphasize the value of continuous monitoring in older adults receiving insulin precisely to reduce unrecognized hypoglycemia.

During pregnancy, insulin remains the reference treatment when nutritional therapy alone is insufficient to control gestational diabetes or when pregestational type 1 or type 2 diabetes is present. Requirements change rapidly across the trimesters as gestational insulin resistance evolves, and control must be particularly accurate to reduce maternal and fetal complications. The postpartum period also requires rapid readjustment, especially in women with type 1 diabetes, whose requirements fall abruptly after delivery.

In the hospital setting, insulin is often the most effective and controllable means of managing hyperglycemia. In critical care units and metabolic emergencies, intravenous infusion permits rapid correction and close monitoring. On general wards, basal-bolus or basal-correction regimens are generally preferable to a reactive correction-only sliding scale, which tends to chase hyperglycemia rather than prevent it. A fundamental principle is that basal insulin should never be completely discontinued in people with type 1 diabetes, because doing so exposes them to ketosis even in the absence of oral intake.

In patients with chronic kidney disease, liver disease, enteral or parenteral nutrition, steroid therapy and perioperative conditions, insulin therapy must be adapted dynamically. No single regimen is universally valid. What is required instead is an understanding of how the biological and therapeutic context is changing insulin pharmacokinetics, endogenous glucose production and the risk of hypo- or hyperglycemia. It is precisely in these settings that clinical experience and close monitoring become decisive.

The principal complication of insulin therapy is hypoglycemia, which may range from mild, self-managed forms to severe episodes requiring external assistance and associated with seizures, trauma or altered consciousness. Its occurrence depends on the interaction among insulin dose, food intake, exercise, kidney function, alcohol consumption, technology used and awareness of adrenergic and neuroglycopenic symptoms. Nocturnal hypoglycemia deserves particular attention because it may remain unrecognized and lead to fear, poor sleep quality and unjustified compensatory dose reduction the following day.

A second common problem is weight gain, especially when treatment rapidly corrects a previous catabolic state or when escalating doses are used in the presence of marked insulin resistance without simultaneously addressing eating habits and sedentary behavior. This phenomenon partly reflects anabolic recovery, partly the cessation of urinary caloric loss caused by glycosuria and partly compensatory carbohydrate intake because of fear or treatment of hypoglycemia.

Local complications include lipohypertrophy, bruising, pain and, more rarely, infections or skin reactions. Lipodystrophy caused by repeated injection into the same site has a much greater clinical impact than is often assumed because it can cause erratic absorption and glycemic fluctuations that are difficult to interpret. Prevention requires periodic inspection of injection sites and continuous reinforcement of site-rotation rules.

The safety of insulin therapy depends decisively on preventing dose errors. These may result from confusion between different pens, improper use of units with concentrated formulations, switching basal and prandial insulin, incorrect transcription in hospital, failure to suspend boluses temporarily during fasting or, conversely, inappropriate suspension of basal insulin in type 1 diabetes. Complex care settings require accurate medication reconciliation, clear prescriptions, staff education and practical verification of the patient's competence.

Diabetic ketoacidosis may also be, indirectly, a complication of inadequate insulin therapy, particularly when the basal dose is omitted, an insulin pump malfunctions or intercurrent illness is managed incorrectly. Safety therefore does not mean avoiding hypoglycemia alone. It means maintaining a balance in which the patient receives enough insulin to prevent catabolic decompensation, but not so much that they are exposed to clinically significant hypoglycemic episodes.

No insulin therapy works well without therapeutic education. Patients must understand the difference between basal and prandial insulin, recognize the symptoms of hypoglycemia, know how to correct it, understand sick-day management, know when to measure glucose or check the sensor, learn injection technique, store devices correctly and interpret the relationship among meals, physical activity and doses. Initial education is not sufficient: it must be reassessed and reinforced over time because real life introduces problems that no single visit can anticipate completely.

Adherence to insulin therapy is hindered by fear of needles, fear of hypoglycemia, social embarrassment about injections, regimen complexity, costs, diabetes burnout, misconceptions and a continuous mental burden. In many patients, the barrier is not technical but emotional and behavioral. Modern care programs therefore emphasize diabetes self-management education and support as a structural rather than ancillary component of insulin therapy.

The future of insulin therapy is developing along several directions. On the one hand, increasingly rapid or more stable insulins with more predictable action profiles are being refined. On the other, increasingly sophisticated automated delivery algorithms are being developed that can improve time in range while reducing the patient's decision-making burden. These developments are accompanied by digital systems supporting carbohydrate counting, telemedicine platforms, sensor-data analysis and tools for personalizing titration in real time.

Despite these advances, the future of insulin therapy will be defined not only by technology but also by accessibility. Quality of care depends on the practical ability to obtain insulin, pens, needles, sensors, insulin pumps and specialist education without financial or organizational barriers. The most recent guidelines strongly emphasize this issue because innovation has genuine clinical value only when it reaches the population that needs it.

In summary, insulin therapy is now a complex clinical discipline that combines endocrinology, pharmacology, education, technology and personalized medicine. Its success depends on the pathophysiological appropriateness of the regimen, precision of titration, operational safety and the ability to integrate treatment into the patient's daily life. When these elements are well coordinated, insulin remains one of the most powerful and transformative therapeutic tools in all of metabolic medicine.